Cancer News and Research

Latest Cancer News and Research

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell Technologies, Inc. has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

14 Jun 2010

Phase Forward Central Coding application achieves UMC's new certification

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding™ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ("Uppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced"), UMC's new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced.

14 Jun 2010

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

NPR continues its examination of medical marijuana: "Fourteen states and the District of Columbia have launched a medical experiment that doesn't follow any of the rules of science. By approving the use of marijuana as a medicine — with varying kinds of restrictions — these jurisdictions are bypassing the federal government's elaborate processes for approving medicines."

14 Jun 2010

BioAMD establishes headquarters at Daresbury SIC

Flex Fuels Energy, Inc. announced today that its subsidiary, BioAMD Holdings Ltd., has established its headquarters at the prestigious Daresbury Science and Innovation Campus in the United Kingdom. BioAMD is in the $12.6 billion Point-of-Care medical diagnostics industry.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

IMF concludes first-of-its-kind inaugural Myeloma Summit

The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, has concluded the first-of-its-kind inaugural Myeloma Summit meeting - nearly 70 of the world's leading experts in myeloma and related blood cancers charting the future of myeloma treatment and care.

14 Jun 2010

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

Celsion Corporation announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology Annual Meeting. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

14 Jun 2010

First Edition: June 14, 2010

Today's health policy headlines report on new White House rules on changes to health insurance benefits, a study regarding employers' medical costs and the likely impact of retirements within the health care workforce.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

New bacterial strain could help in long-term cleanup of oil spills

Researchers have discovered a new strain of bacteria that can produce non-toxic, comparatively inexpensive "rhamnolipids," and effectively help degrade polycyclic aromatic hydrocarbons, or PAHs - environmental pollutants that are one of the most harmful aspects of oil spills.

14 Jun 2010

Nurse with enhanced clinical skills detects same breast abnormalities as surgeon

UK researchers have developed an Initiative that could help hospitals prevent delays to the two-week cancer target, following the reduction in junior doctors' working hours due to the European Working Time Directive. A specially trained nurse practitioner and consultant breast surgeon who examined 126 women referred to a symptomatic breast disease clinic picked up the same breast abnormalities in 92% of cases.

14 Jun 2010

Researchers report 4 pillars of preventive medicine for AD

Although effective treatment for Alzheimer's disease has been slow to emerge, there has been substantial progress in identifying AD risk factors and developing treatments that might delay or prevent onset of the disease. In a Special Issue of the Journal of Alzheimer's Disease, "Basics of Alzheimer's Disease Prevention," researchers report on key findings that point towards possible significant interventions.

14 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Fluorescent cancerous tumors for early detection

UCB announces availability of Vimpat oral solution formulation

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

Phase Forward Central Coding application achieves UMC's new certification

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

BioAMD establishes headquarters at Daresbury SIC

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Healthcore Media launches dynamic, educational and community-oriented health website

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

New research evaluating substantial disease burden of PNH presented at European Hematology Association

IMF concludes first-of-its-kind inaugural Myeloma Summit

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

First Edition: June 14, 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

New bacterial strain could help in long-term cleanup of oil spills

Nurse with enhanced clinical skills detects same breast abnormalities as surgeon

Researchers report 4 pillars of preventive medicine for AD

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in